Summary

Although the study failed to meet its primary endpoint, results from the ATOLL study indicate that the low-molecular-weight heparin enoxaparin may provide better clinical outcomes than unfractionated heparin in ST-elevation myocardial infarction patients who are undergoing primary percutaneous coronary intervention.